Enzalutamide is a second-generation nonsteroidal antiandrogen that has recently been approved for the same indication.
Sometimes the same drug, in the same dosage and for the same indication, was sold both ways.
The comparison group was comprised of 297 patients aged 75 to 84 years who were hospitalized for the same indication in the same time period.
However, there exist essential differences in the evaluation of the efficacy and safety of a TCM as compared with a typical Western medicine (WM), even though they are for the same indication.
Trametinib is a MEK inhibitor approved for the same indication, as well as for a combination with Dabrafenib [2].
Denosumab is a fully human monoclonal antibody that inactivates receptor activator of nuclear factor-κB ligand and is approved for the same indication.
For re-assessments of products for the same indication following additional data being filed by the manufacturer, only the latest assessment was included.
During follow-up, 70 of 450 patients with abdominal pain (15%), 53 of 387 with chest pain and/or dyspnea (14%), and 49 of 433 with headache (11%) returned for the same indication.
Some drugs were reviewed multiple times for the same indication.
It was approved in the EU in April 2008 for the same indication [ 14, 15].
In June 2007, the European Medicines Agency approved lenalidomide for the same indication.
